MODERN APPROACHES TO THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TRANQUILIZERS IN PSYCHIATRIC DISORDERS
Keywords:
benzodiazepines; tranquilizers; pharmacodynamics; pharmacokinetics; psychiatric disorders; precision psychiatry; pharmacogenomics; therapeutic drug monitoring; GABA-A receptor; individualized therapy.Abstract
Tranquilizers, particularly benzodiazepine receptor agonists, remain clinically relevant for the short-term management of anxiety, severe agitation, insomnia, catatonia, and selected withdrawal states. Their clinical effects are determined by an interaction between absorption, distribution, metabolism, elimination, receptor pharmacology, active metabolites, dosing interval, tolerance, and patient-specific vulnerability. Modern pharmacology increasingly moves from a drug-centered approach toward individualized treatment based on pharmacokinetic-pharmacodynamic (PK-PD) integration, therapeutic drug monitoring (TDM) when clinically justified, pharmacogenomics, drug-interaction assessment, and quantitative exposure-response modeling. This review summarizes contemporary concepts in the PK and PD of tranquilizers used in psychiatric practice, with particular attention to benzodiazepines, differences between short-, intermediate-, and long-acting compounds, hepatic metabolism, active metabolites, receptor selectivity, tolerance, dependence, withdrawal, and clinically important interactions. Evidence also supports cautious application of pharmacogenetic information, although routine genotype-guided dosing of benzodiazepines is not yet sufficiently validated for universal clinical use. Modern prescribing should therefore combine indication-specific selection, the lowest effective dose, the shortest reasonable duration, reassessment of benefit and harm, and individualized tapering. The emerging direction is precision psychopharmacology, in which clinical phenotype, PK-PD characteristics, comorbidity, co-medications, age, organ function, and, where evidence supports it, genetic information are integrated to optimize efficacy and safety.
References
1.American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081.
2.Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, et al. Benzodiazepine dependence: focus on withdrawal syndrome and pharmacological management. Pharmacol Res. 2009;59(5):293-302.
3.Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2):17.
4.Hart XM, et al. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics. World J Biol Psychiatry. 2024;25(9):451-536.
5.Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 16th ed. New York: McGraw Hill; 2024.
6.Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet. 1996;30(1):52-76.
7.Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Can J Clin Pharmacol. 1999;6(2):69-83.
8.Palumbo S, Mariotti V, Pellegrini S. A narrative review on pharmacogenomics in psychiatry: scientific definitions, principles, and practical resources. J Clin Psychopharmacol. 2024;44(1):49-56.
9.Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147-1157.
10.Teboul E, Chouinard G. A guide to benzodiazepine selection. Part II: Clinical aspects. Can J Psychiatry. 1991;36(1):62-73.
11.Vuilleumier P, et al. Using pharmacokinetics and pharmacogenetics to optimize psychiatric treatments: a systematic review. Eur Neuropsychopharmacol. 2022;58:1-16.
